Tenofovir Disoproxil Fumarate
NDC Package 69025-101-01
Package Information
Tenofovir Disoproxil Fumarate is tenofovir is used with other HIV medications to help control HIV infection. Marketed by Aizant Drug Research Solutions Pvt Ltd, this product is identified by NDC 69025-101.
Identification & Billing
- RxCUI: 1243227 - tenofovir disoproxil fumarate 250 MG Oral Tablet
- RxCUI: 1243227 - tenofovir disoproxil fumarate 250 MG (equivalent to tenofovir disoproxil 204 MG) Oral Tablet
- RxCUI: 1243324 - tenofovir disoproxil fumarate 150 MG Oral Tablet
- RxCUI: 1243324 - tenofovir disoproxil fumarate 150 MG (equivalent to tenofovir disoproxil 123 MG) Oral Tablet
- RxCUI: 1243328 - tenofovir disoproxil fumarate 200 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69025 - Aizant Drug Research Solutions Pvt Ltd
- 69025-101 - Tenofovir Disoproxil Fumarate
- 69025-101-01 - 30 TABLET, FILM COATED in 1 BOTTLE
- 69025-101 - Tenofovir Disoproxil Fumarate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69025-101-01 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Tenofovir Disoproxil Fumarate, labeled by Aizant Drug Research Solutions Pvt Ltd. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Aizant Drug Research Solutions Pvt Ltd on January 26, 2018. The current certification is valid through December 31, 2017.
What are the primary indications for this medication?
Tenofovir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Tenofovir belongs to a class of drugs known as nucleotide reverse transcriptase inhibitors (NRTIs). Tenofovir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, do all of the following: (1) continue to take all HIV medications exactly as prescribed by your doctor, (2) always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity, and (3) do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. Tenofovir is also used to treat a certain type of liver infection called chronic hepatitis B infection. It helps to decrease the amount of hepatitis B virus in your body by interfering with virus growth.
How is this Aizant Drug Research Solutions Pvt Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69025010101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.